INS and Abdominal obesity: Compared with increasing the insulin dose therapy, the present study demonstrated the beneficial effects of adding the long-acting GLP-1 analog liraglutide to established insulin therapy, which resulted in a significant improvement in glycemic control, reduction in insulin requirement, lower incidence of hypoglycemia events and weight loss in the Chinese patients with poorly controlled T2D and abdominal obesity.